CD95 Is Part of a Let-7/p53/miR-34 Regulatory Network

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Hau, Annika ^a   Ceppi, Paolo ^a   Peter, Marcus E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; MICRORNA 34A; PROTEIN LET 7; PROTEIN P53; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC REGULATION; GENOTOXICITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

ANTIGENS, CD95; APOPTOSIS; CELL LINE, TUMOR; DNA DAMAGE; EPISTASIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENE SILENCING; HUMANS; MICRORNAS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84869124903     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049636     Document Type: Article

References (78)

1. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, et al. (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243.
2. Yonehara S, Ishii A, Yonehara M, (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747-1756.
3. Peter ME, Legembre P, Barnhart BC, (2005) Does CD95 have tumor promoting activities? BBA 1755: 25-36.
4. Papenfuss K, Cordier SM, Walczak H, (2008) Death receptors as targets for anti-cancer therapy. J Cell Mol Med 12: 2566-2585.
5. Peter ME, Barnhart BC, Algeciras-Schimnich A (2003) The Cytokine Handbook: CD95L/FasL and its receptor CD95 (APO-1/Fas); Thomson AW, Lotze MT, editors. London: Academic Press. 885-911 p.
6. Del-Rey M, Ruiz-Contreras J, Bosque A, Calleja S, Gomez-Rial J, et al. (2006) A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood 108: 1306-1312.
7. Barnhart BC, Alappat EC, Peter ME, (2003) The CD95 type I/type II model. Sem Immunol 15: 185-193.
8. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, et al. (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675-1687.
9. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, et al. (2008) Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma. Cancer Cell 13: 235-248.
10. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, et al. (2010) CD95 promotes tumour growth. Nature 465: 492-496.
11. Desbarats J, Newell MK, (2000) Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 6: 920-923.
12. Corsini NS, Sancho-Martinez I, Laudenklos S, Glagow D, Kumar S, et al. (2009) The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 5: 178-190.
13. La OR, Tai L, Lee L, Kruse EA, Grabow S, et al. (2009) Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 461: 659-663.
14. Peter ME, (2009) Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8: 843-852.
15. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, et al. (2007) Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 104: 11400-11405.
16. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
17. Ghildiyal M, Zamore PD, (2009) Small silencing RNAs: an expanding universe. Nature Rev Genetics 10: 94-108.
18. Hwang HW, Mendell JT, (2006) MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94: 776-780.
19. Friedman RC, Farh KK, Burge CB, Bartel DP, (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
20. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME, (2010) The role of let-7 in cell differentiation and cancer. Endocr-Rel cancer 17: F19-36.
21. Geng L, Zhu B, Dai BH, Sui CJ, Xu F, et al. (2011) A let-7/Fas double-negative feedback loop regulates human colon carcinoma cells sensitivity to Fas-related apoptosis. Biochem Biophys Res Commun 408: 494-499.
22. Algeciras-Schimnich A, Pietras EM, Barnhart BC, Legembre P, Vijayan S, et al. (2003) Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci USA 100: 11445-11450.
23. Park SM, Gaur AB, Lengyel E, Peter ME, (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors, ZEB1 and ZEB2. Genes Dev 22: 894-907.
24. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, et al. (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188: 2033-2045.
25. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134.
26. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731-743.
27. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745-752.
28. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, et al. (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17: 1298-1307.
29. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, et al. (2007) Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586-1593.
30. Maecker HL, Koumenis C, Giaccia AJ, (2000) p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Res 60: 4638-4644.
31. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, et al. (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092.
32. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, et al. (1998) Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282: 290-293.
33. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300.
34. Grande SM, Bannish G, Fuentes-Panana EM, Katz E, Monroe JG, (2007) Tonic B-cell and viral ITAM signaling: context is everything. Immunol Rev 218: 214-234.
35. Meng XW, Peterson KL, Dai H, Schneider P, Lee SH, et al. (2011) High cell surface death receptor expression determines type I versus type II signaling. J Biol Chem 286: 35823-35833.
36. Hermeking H, (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17: 193-199.
37. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, et al. (2010) Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16: 1119-1128.
38. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, et al. (2008) A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 6: 735-742.
39. Shi M, Liu D, Shen B, Guo N, (2010) Helpers of the cellular gatekeeper-miRNAs dance in P53 network. BBA 1805: 218-225.
40. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, et al. (2010) p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 17: 236-245.
41. Debatin KM, Krammer PH, (2004) Death receptors in chemotherapy and cancer. Oncogene 23: 2950-2966.
42. Mielgo A, van Driel M, Bloem A, Landmann L, Gunthert U, (2006) A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ 13: 465-477.
43. Zou C, Ma J, Wang X, Guo L, Zhu Z, et al. (2007) Lack of Fas antagonism by Met in human fatty liver disease. Nat Med 13: 1078-1085.
44. Hua Y, Duan S, Murmann AE, Larsen N, Kjems J, et al. (2011) miRConnect: Identifying Effector Genes of miRNAs and miRNA Families in Cancer Cells. PLoS ONE 6: e26521.
45. Hua YJ, Larsen N, Kalyana-Sundaram S, Kjems J, Chinnaiyan AM, et al. miRConnect 2.0: Identification of antagonistic, oncogenic miRNA families in three human cancers. Submitted.
46. Yamakuchi M, Ferlito M, Lowenstein CJ, (2008) miR-34a repression of SIRT1 regulates apoptosis. Proceedings of the National Academy of Sciences of the United States of America 105: 13421-13426.
47. Schickel R, Park SM, Murmann AE, Peter ME, (2010) mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 38: 908-915.
48. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, et al. (2011) p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13: 317-323.
49. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, et al. (2011) p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 208: 875-883.
50. Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, et al. (2011) miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10: 4256-4271.
51. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, et al. (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 403-413.
52. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, et al. (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032-3040.
53. Munsch D, Watanabe-Fukunaga R, Bourdon JC, Nagata S, May E, et al. (2000) Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J Biol Chem 275: 3867-3872.
54. Schilling T, Schleithoff ES, Kairat A, Melino G, Stremmel W, et al. (2009) Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family. Biochem Biophys Res Commun 387: 399-404.
55. Saleh AD, Savage JE, Cao L, Soule BP, Ly D, et al. (2011) Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. PLoS ONE 6: e24429.
56. Wang S, Tang Y, Cui H, Zhao X, Luo X, et al. (2011) Let-7/miR-98 regulate Fas and Fas-mediated apoptosis. Genes Immun 12: 149-154.
57. Clevers H, (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-319.
58. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
59. Wilson KD, Venkatasubrahmanyam S, Jia F, Sun N, Butte AJ, et al. (2009) MicroRNA profiling of human-induced pluripotent stem cells. Stem Cells Dev 18: 749-758.
60. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, et al. (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138: 592-603.
61. Ji Q, Hao X, Zhang M, Tang W, Yang M, et al. (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 4: e6816.
62. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S, (2011) Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS ONE 6: e24099.
63. Choi YJ, Lin CP, Ho JJ, He X, Okada N, et al. (2011) miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol 13: 1353-1360.
64. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215.
65. Yu F, Yao H, Zhu P, Zhang X, Pan Q, et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123.
66. Hong Y, Stambrook PJ, (2004) Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation. Proc Natl Acad Sci USA 101: 14443-14448.
67. Richards M, Tan SP, Tan JH, Chan WK, Bongso A, (2004) The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells 22: 51-64.
68. Semont A, Nowak EB, Silva Lages C, Mathieu C, Mouthon MA, et al. (2004) Involvement of p53 and Fas/CD95 in murine neural progenitor cell response to ionizing irradiation. Oncogene 23: 8497-8508.
69. Knight JC, Scharf EL, Mao-Draayer Y, (2010) Fas activation increases neural progenitor cell survival. J Neurosci Res 88: 746-757.
70. Beier CP, Schulz JB, (2009) CD95/Fas in the brain-not just a killer. Cell Stem Cell 5: 128-130.
71. Zuliani C, Kleber S, Klussmann S, Wenger T, Kenzelmann M, et al. (2006) Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death Differ 13: 31-40.
72. Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS, et al. (2003) Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 5: 118-125.
73. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, et al. (2011) A human memory T cell subset with stem cell-like properties. Nat Med 17: 1290-1297.
74. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
75. Medema JP, Scaffidi C, Krammer PH, Peter ME, (1998) Bcl-xL acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex. J Biol Chem 273: 3388-3393.
76. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, et al. (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67: 2456-2468.
77. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, et al. (2007) The CD95 receptor: apoptosis revisited. Cell 129: 447-450.
78. Peter ME, Legembre P, Barnhart BC, (2005) Does CD95 have tumor promoting activities? Biochim Biophys Acta 1755: 25-36.